We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$415M
AUM Growth
+$35.8M
Cap. Flow
+$32.9M
Cap. Flow %
7.93%
Top 10 Hldgs %
52.35%
Holding
76
New
10
Increased
22
Reduced
9
Closed
8
Avg Time Held
1.8 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
1.4 years

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$15.5M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$13.1M
3
ILMN icon
Illumina
ILMN
+$12.8M
4
INCY icon
Incyte
INCY
+$10.1M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$7.79M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$18.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.9M
3
UTHR icon
United Therapeutics
UTHR
+$7.77M
4
XLRN
Acceleron Pharma
XLRN
+$7.59M
5
BIIB icon
Biogen
BIIB
+$7.54M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GILD icon
1
Gilead Sciences
GILD
$195B
$28.1M 6.78%
402,784
– –
2016 Q4
19 quarters
NBIX icon
2
Neurocrine Biosciences
NBIX
$13.9B
$27.7M 6.69%
289,500
+82,500
+40% +$7.79M
2017 Q3
16 quarters
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$26M 6.28%
237,873
– –
2016 Q4
19 quarters
AMGN icon
4
Amgen
AMGN
$235B
$25.1M 6.06%
118,300
+67,300
+132% +$15.5M
2018 Q4
11 quarters
BHVN icon
5
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$24.5M 5.91%
176,400
– –
2020 Q2
5 quarters
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
$18.6M 4.49%
109,700
-35,300
-24% -$5.49M
2017 Q1
18 quarters
INCY icon
7
Incyte
INCY
$23B
$18.6M 4.48%
270,360
+133,500
+98% +$10.1M
2016 Q4
19 quarters
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$17.4M 4.2%
98,500
+81,600
+483% +$13.1M
2019 Q1
10 quarters
PTCT icon
9
PTC Therapeutics
PTCT
$5.09B
$16.7M 4.03%
449,000
– –
2019 Q1
10 quarters
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$31.3B
$14.2M 3.42%
75,000
-74,000
-50% -$13.9M
2017 Q3
16 quarters
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$129B
$14M 3.38%
77,222
+12,400
+19% +$2.42M
2016 Q4
19 quarters
ILMN icon
12
Illumina
ILMN
$40.5B
$10.9M 2.64%
+27,756
New +$12.8M
2021 Q3
0 quarters
EXEL icon
13
Exelixis
EXEL
$15.6B
$10.3M 2.49%
489,534
+388,000
+382% +$7.21M
2016 Q4
19 quarters
RARE icon
14
Ultragenyx Pharmaceutical
RARE
$1.5B
$9.29M 2.24%
103,100
+43,000
+72% +$3.89M
2021 Q1
2 quarters
TPTX
15
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$9.22M 2.22%
138,741
+17,200
+14% +$1.23M
2019 Q4
7 quarters
TVTX icon
16
Travere Therapeutics
TVTX
$4.98B
$9.21M 2.22%
380,000
+360,000
+1,800% +$6.61M
2020 Q4
3 quarters
HRMY icon
17
Harmony Biosciences
HRMY
$2.23B
$9.02M 2.18%
236,000
+70,000
+42% +$2.25M
2021 Q2
1 quarter
SUPN icon
18
Supernus Pharmaceuticals
SUPN
$2.3B
$7.93M 1.91%
297,500
+95,064
+47% +$2.55M
2021 Q2
1 quarter
BIIB icon
19
Biogen
BIIB
$34.8B
$7.21M 1.74%
25,500
-23,000
-47% -$7.54M
2018 Q4
11 quarters
CCXI icon
20
DELISTED
ChemoCentryx, Inc.
CCXI
$7.13M 1.72%
94,300
+36,200
+62% +$564K
2020 Q1
6 quarters
KALV icon
21
DELISTED
KalVista Pharmaceuticals
KALV
$6.69M 1.61%
383,233
+100,000
+35% +$2.03M
2016 Q4
19 quarters
INSM icon
22
Insmed
INSM
$21.7B
$6.64M 1.6%
241,100
+141,000
+141% +$3.7M
2019 Q1
10 quarters
QURE icon
23
uniQure
QURE
$1.56B
$5.83M 1.41%
182,194
-133,306
-42% -$4.06M
2019 Q2
9 quarters
JAZZ icon
24
Jazz Pharmaceuticals
JAZZ
$13.9B
$5.75M 1.39%
44,200
+24,200
+121% +$3.66M
2021 Q2
1 quarter
ASND icon
25
Ascendis Pharma A/S
ASND
$14.9B
$4.69M 1.13%
29,400
+15,600
+113% +$2.13M
2019 Q1
10 quarters
1
2 3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2021 Portfolio in Review

As of Q3 2021, International Biotechnology Trust held 76 positions worth $415M, up 9.5% from $379M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

International Biotechnology Trust deployed $32.9M of net new capital in Q3 2021, opening 10 new positions and adding to 22 existing holdings. Its largest new stake was Illumina: 27,756 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $18.3M trimmed.

  • International Biotechnology Trust's largest Q3 2021 buy was Illumina: 27,756 shares worth $10.9M.
  • International Biotechnology Trust added most to Amgen in Q3 2021, an estimated $15.5M increase.
  • International Biotechnology Trust's biggest Q3 2021 reduction was Regeneron Pharmaceuticals, cutting an estimated $18.3M.
  • International Biotechnology Trust fully exited United Therapeutics in Q3 2021, selling an estimated $7.77M.
  • International Biotechnology Trust's ten largest holdings make up 52% of its $415M portfolio in Q3 2021.
  • International Biotechnology Trust opened 10 new positions and closed 8 in Q3 2021.
  • International Biotechnology Trust's portfolio value rose 9.5% quarter-over-quarter to $415M.

Based on International Biotechnology Trust's 13F filing for Q3 2021, filed 12 Nov 2021.